These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Citrome L; Meng X; Hochfeld M; Stahl SM Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738 [TBL] [Abstract][Full Text] [Related]
5. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. Vieta E; Ramey T; Keller D; English PA; Loebel AD; Miceli J J Psychopharmacol; 2010 Apr; 24(4):547-58. PubMed ID: 19074536 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. Stahl S; Lombardo I; Loebel A; Mandel FS J Affect Disord; 2010 Apr; 122(1-2):39-45. PubMed ID: 19616304 [TBL] [Abstract][Full Text] [Related]
7. A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder. Patkar AA; Pae CU; Vöhringer PA; Mauer S; Narasimhan M; Dalley S; Loebel A; Masand PS; Ghaemi SN J Clin Psychopharmacol; 2015 Jun; 35(3):319-23. PubMed ID: 25882763 [TBL] [Abstract][Full Text] [Related]
8. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909 [TBL] [Abstract][Full Text] [Related]
9. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Martel M; Sterzinger A; Miner J; Clinton J; Biros M Acad Emerg Med; 2005 Dec; 12(12):1167-72. PubMed ID: 16282517 [TBL] [Abstract][Full Text] [Related]
10. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial. Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845 [TBL] [Abstract][Full Text] [Related]
13. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Biederman J; Mick E; Spencer T; Dougherty M; Aleardi M; Wozniak J Bipolar Disord; 2007 Dec; 9(8):888-94. PubMed ID: 18076539 [TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348 [TBL] [Abstract][Full Text] [Related]
15. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373 [TBL] [Abstract][Full Text] [Related]
17. Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial. Jeon HJ; Fava M; Mischoulon D; Baer L; Clain A; Doorley J; DiPierro M; Cardoos A; Papakostas GI Int Clin Psychopharmacol; 2014 Nov; 29(6):332-8. PubMed ID: 24815673 [TBL] [Abstract][Full Text] [Related]
18. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR; J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817 [TBL] [Abstract][Full Text] [Related]
20. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. Patkar A; Gilmer W; Pae CU; Vöhringer PA; Ziffra M; Pirok E; Mulligan M; Filkowski MM; Whitham EA; Holtzman NS; Thommi SB; Logvinenko T; Loebel A; Masand P; Ghaemi SN PLoS One; 2012; 7(4):e34757. PubMed ID: 22545088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]